X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Sertraline is one of the most frequently prescribed antidepressants in the world and belongs to the group of the selective serotonin reuptake inhibitors (SSRIs). About 5 million people in Germany take antidepressants (a German figure, broadly comparable across Western countries), many of them sertraline as a first-line therapy with depression or an anxiety disorder. Unlike citalopram, sertraline has a lower risk of QT prolongation — but sexual side effects, affecting 30-70%, are a common taboo topic.
See more detail.gif)
Never stop sertraline abruptly — a discontinuation syndrome is common. Onset latency 2–6 weeks. For suicidal thoughts, Telefonseelsorge 0800 1110111 (a German crisis helpline); in an acute crisis call the emergency services (112; or 999/112 in the UK). On suspicion of serotonin syndrome, call the emergency services immediately (112; or 999/112 in the UK). Last updated: May 2026.
Sertraline is one of the most frequently prescribed SSRIs and a first-line antidepressant in outpatient practice. Below are the key facts for quick orientation; the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Sertraline — selective serotonin reuptake inhibitor (SSRI) |
| ATC code | N06AB06 — selective serotonin reuptake inhibitors |
| Mechanism of action | Inhibition of the serotonin transporter (SERT) — raises serotonin in the synaptic cleft; secondary neuronal adaptations |
| Main indications | Depression, anxiety disorders, panic disorder, obsessive-compulsive disorder, PTSD, social phobia, PMDD |
| Usual dose | Start 25–50 mg/day, target dose 50–200 mg/day, once daily |
| Onset latency | 2–6 weeks (depression), up to 12 weeks (obsessive-compulsive disorder) |
| Half-life | About 26 hours |
| Metabolism | Liver via CYP2C19, CYP2B6, CYP3A4, CYP2D6 |
| QT risk | Low — favourable in heart patients |
| Most severe risks | Serotonin syndrome, hyponatraemia, bleeding tendency; an increase in suicidality in the first weeks (especially in those under 25) |
| Important warning | Never stop abruptly — SSRI discontinuation syndrome is common; taper over 2–8 weeks |
| Prescription status | Yes |
Sertraline is a selective serotonin reuptake inhibitor (SSRI) and is one of the most frequently prescribed antidepressants in Germany. It is used both for depression and for a variety of anxiety disorders, obsessive-compulsive disorders, post-traumatic stress disorders and premenstrual syndrome. Compared with other SSRIs, sertraline is regarded as well tolerated, which is why it is often recommended as a first-line medicine in outpatient practice.
Sertraline was developed in the 1980s and first approved in 1991. It belongs to the second generation of antidepressants — after the older tricyclic antidepressants (TCAs), which are effective but carry considerably more side effects. SSRIs revolutionised antidepressant therapy because they are considerably better tolerated and less dangerous in overdose. Sertraline is one of the most frequently prescribed medicines worldwide.
Important to understand: sertraline is not a "happy pill" that lifts the mood in the short term, but a medicine that treats the underlying neurobiological dysfunction in depression and anxiety disorders. The effect builds up over weeks — the first days and weeks are often demanding, because side effects occur before the actual effect. This "onset latency" is often communicated inadequately in the consultation and is one of the most common causes of premature discontinuation of therapy.
Sertraline belongs to the selective serotonin reuptake inhibitors (SSRIs). Its mechanism of action at the nerve cell is well researched — its translation into the clinical effect, however, is not yet fully understood. What we know:
In the brain, nerve cells communicate via chemical messengers — so-called neurotransmitters. Serotonin is one of the most important of these messengers and regulates mood, anxiety, sleep, appetite, pain perception and much more. When a nerve cell releases serotonin into the synaptic cleft, it is normally quickly pumped back into the cell — via the serotonin transporter (SERT). Sertraline blocks this transporter and thereby ensures that serotonin remains available in the synaptic cleft for longer.
However: raising serotonin alone would not explain the antidepressant effect — because this rise occurs within hours, but the antidepressant effect only after weeks. Today it is assumed that there are secondary adaptation processes in the nerve cell: changes in receptor density and sensitivity, neuroplasticity (the formation of new nerve connections), the adaptation of other neurotransmitter systems (noradrenaline, dopamine). These processes take time — and explain the typical onset latency of 2 to 6 weeks.
Sertraline is well absorbed after oral intake, reaches maximum plasma levels after 4 to 8 hours and has a half-life of about 26 hours — hence the once-daily intake. Metabolism occurs predominantly in the liver via several CYP enzymes (CYP2C19, CYP2B6, CYP3A4, CYP2D6). Compared with other SSRIs, sertraline has a moderate interaction profile — lower than fluoxetine or fluvoxamine, similar to citalopram or escitalopram.
The most common indication. In moderate to severe depression, sertraline is an established first-line medicine. Its effectiveness and tolerability are very well documented — about half of patients experience a marked improvement, a further 20 to 30 percent benefit partially. Therapy usually comprises an acute phase of 6 to 12 weeks (aiming for symptom remission) and maintenance therapy of at least 6 to 9 months (sometimes longer) to avoid relapses.
In anxiety disorders, sertraline is regarded as one of the first-line options. In panic disorders it improves both the attack frequency and the severity — an important particularity: at the start of therapy a paradoxical intensification of anxiety symptoms can occur. Therefore, in anxiety disorders an even lower starting dose (12.5–25 mg) and very slow up-titration are used, often with bridging accompanying medication (e.g. a low-dose benzodiazepine or pregabalin).
Sertraline is one of the few antidepressants explicitly approved for the treatment of obsessive-compulsive disorder. In obsessive-compulsive disorders, higher doses are often needed than in depression (up to 200 mg/day), and the onset latency can be longer (up to 12 weeks).
Sertraline is explicitly approved in the USA for the treatment of PTSD and is one of the recommended first-line medicines in German guidelines. It improves symptoms such as intrusions, avoidance behaviour and hyperarousal. As a rule combined with trauma-focused psychotherapy.
In social anxiety disorders (e.g. fear of speaking, generalised social phobia), sertraline is effective and established. Combination with behavioural therapy is standard.
In severe premenstrual dysphoria, sertraline can be taken either continuously or only in the second half of the cycle (luteal phase) — the latter approach is a particularity among the SSRIs and well documented.
The correct dosing of sertraline depends on the indication and the individual tolerability. Very important: always start SSRIs gradually — abruptly starting at the target dose massively intensifies the initial side effects and frequently leads to discontinuation of therapy:
| Indication | Starting dose | Target dose |
|---|---|---|
| Depression in adults | 50 mg/day in the morning | 50–200 mg/day |
| Generalised anxiety disorder / panic disorder | 25 mg/day for 7 days, then 50 mg | 50–200 mg/day |
| Obsessive-compulsive disorder | 50 mg/day | 100–200 mg/day (often higher) |
| PMDD with luteal therapy | 50 mg/day in the 14 days before the period | 50 mg/day |
| Older patients | 25 mg/day | Slow increase |
| Hepatic impairment | Half the standard dose | Cautious titration |
| Renal impairment | No adjustment required | Standard dosing |
One of the most important messages for patients: sertraline does not work acutely. The typical onset latency is 2 to 6 weeks in depression, up to 12 weeks in obsessive-compulsive disorders. During this time, side effects often occur first, the effect only afterwards. Those who do not hold on give up an effective therapy before it had its chance.
Important to know: this onset latency applies to all SSRIs and SNRIs. It is not a "deficiency" of the medicines, but an expression of the underlying adaptation processes in the nerve cells. In anxiety disorders the effect can set in earlier, in obsessive-compulsive disorders often later. Patience and realistic expectations are decisive.
Sertraline is overall well tolerated — severe side effects are rare. Frequently occurring side effects (more than 1 in 100 users) are:
Occasionally (1 in 100 to 1 in 1,000):
Sexual side effects are one of the most common and most taboo side effects of all SSRIs — depending on the study, they affect 30 to 70 percent of users, often more reported by women than men, and only at all when actively asked about. Typical are:
What to do: these side effects are unfortunately often not raised in the consultation — neither by doctors nor by patients. Open communication is important. Options for distressing symptoms are: dose reduction (often already helpful), a "drug holiday" (an intake pause at the weekend — controversially discussed), a switch to an SSRI with a lower profile (bupropion is considerably better here, but not approved in Germany for this indication) or mirtazapine, the addition of sildenafil for erectile dysfunction (off-label), psychotherapy for coping.
Rare but important side effects:
Life-threatening, especially in combination with other serotonergic substances (other SSRIs/SNRIs, MAO inhibitors, triptans, tramadol, linezolid, methylene blue, MDMA, St John's wort). Symptoms: mental changes (restlessness, confusion), autonomic symptoms (sweating, a racing heart, high blood pressure, dilated pupils, fever), neuromuscular symptoms (tremor, muscle twitches, hyperreflexia, clonus).
SSRIs can excessively stimulate the antidiuretic hormone (ADH) — with reduced sodium excretion. The consequence: hyponatraemia, especially in older patients. Symptoms: fatigue, confusion, headaches, in the extreme case seizures and unconsciousness. Regular sodium checks in older patients, especially in the first weeks and with co-medication of diuretics.
SSRIs inhibit serotonin uptake into platelets and impair platelet function. An increased risk of: gastrointestinal bleeding (especially in combination with NSAIDs or anticoagulants), perioperative bleeding, nosebleeds, mild bruising. With surgery planning, consult a doctor.
Compared with citalopram, sertraline has a low risk of QT prolongation and is therefore often the better choice in at-risk patients. In patients with known QT prolongation or combination with other QT-prolonging medicines, caution is nevertheless advised.
In a previously unrecognised bipolar disorder, an SSRI can trigger a manic or hypomanic episode. With every new antidepressant therapy, careful history-taking about earlier manic symptoms.
